fepblue glp 1 coverage The GLP-1 Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs More GLP-1 options are coming

If you have a primary care provider you trust who is experienced with these medications, that can be an excellent option

RA, receptor agonist

The FDA states that exenatide, the first GLP-1 receptor agonist, is being phased out as of January 2025 due to a GLP-1 scarcity

, Dewey, S

While I'm not a medical professional, from my research and personal experience, it seems to stem from a few factors

The consistency of findings across multiple retrospective cohorts and data sources provides a compelling signal of efficacy on clinical endpoints, justifying a shift in research focus: the field now needs adequately powered phase 3 randomized controlled trials to validate these preliminary findings [58], define optimal treatment strategies such as dosing and treatment duration, and establish the role of GLP-1 RAs in both acute and long-term management of IIH